ClinicalTrials.gg
CompletedNCT02128542VALOR-HCVUpdated Aug 3, 2016Results posted

Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis

A Phase 4 interventional study of Sofosbuvir and RBV in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-03.

Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies testing sofosbuvir in Hepatitis C — 1 open to participants now, 3 under way, none of them phase 3. Sofosbuvir · Hepatitis C.

Enrollment
50th of 94
66 · median 75
Started
2014
with 10 others
Phase 4
22 of 94
none open now
Registered
24th of 94
by date
Lead sponsor
30 of 94
Gilead Sciences

Among the 94 studies testing sofosbuvir in Hepatitis C, this one is the 50th largest by enrollment, is one of 11 that started in 2014, is one of 22 in phase 4, and was the 24th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

1 of the 94 studies testing sofosbuvir in Hepatitis C is open now. Recruiting first, the newest first:

About sofosbuvir

Sofosbuvir: first FDA approval 2013 (SOVALDI), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing sofosbuvir in Hepatitis C, or all of them as a file.
02

Study summary

This study will examine the safety, tolerability, and antiviral efficacy of sofosbuvir (SOF)+ribavirin (RBV) in treatment-naive and treatment-experienced United States Veterans with compensated cirrhosis and genotype 2 HCV infection.

03

Conditions studied

  • Hepatitis C Virus Infection

Browse trials for

Keywords

  • Veterans HCV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide written .
  • Treatment-naive or treatment-experienced adult, U.S. Veteran
  • Chronic genotype 2 (GT2) infection Classified as:

    • Eligible for treatment with interferon (IFN)-based therapy
    • Ineligible for IFN treatment
    • Intolerant to IFN.
  • Cirrhosis determination
  • Laboratory parameters within prespecified ranges at screening:
  • A negative serum pregnancy test is required for females of
  • Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of
  • Lactating females must agree to discontinue nursing before study drug is administered.
  • Males must agree to refrain from sperm donation from the date of screening until at least 7 months after the last dose of RBV, or 90 days after their last dose of study drug if not taking RBV.
  • Must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments.
  • Must be of generally good health as determined by the Investigator.

Exclusion criteria

Exclusion Criteria:

  • Current participation in an interventional clinical trial.
  • Infection with virus (HBV) or (HIV).
  • History of any other chronic liver disease (e.g., hemochromatosis; Wilson's disease; α1-antitrypsin deficiency), except nonalcoholic steatohepatitis (NASH).
  • Decompensated liver
  • History of hemoglobinopathies
  • or to RBV
  • History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the participation for the full duration of the study, such that it is not in the best interest of the individual to participate.
  • Clinically significant abnormality at screening.
  • History of solid organ transplantation.
  • Presence of hepatocellular carcinoma (HCC) within 5 years prior to screening, with the exception of specific cancers that are entirely cured by surgical resection (basal cell skin cancer and prostate cancer in remission). Individuals under evaluation for possible malignancy are not eligible.
  • Prior treatment with an NS5B polymerase inhibitor.
  • Chronic use of systemic agents or immunomodulatory agents (e.g., prednisone equivalent > 10 mg/day).
  • Concomitant disallowed as per the Sovaldi Packet Insert.
  • Known hypersensitivity to the study drug, the metabolites, or formulation .
  • History of difficulty with blood collection and/or poor venous access for the purposes of phlebotomy.
  • Use of any prohibited concomitant medications as described in the study protocol
  • Gastrointestinal disorder or post-operative condition that could interfere with the absorption of the study drug.
  • Male with pregnant female partner.
  • In the judgment of the investigator any clinically-relevant drug or alcohol abuse within 12 months of screening that may interfere with treatment, assessment or compliance with the protocol.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Sofosbuvir+RBV 12 weeks

    Participants will receive sofosbuvir+RBV for 12 weeks.

    Drug: Sofosbuvir · Drug: RBV

Interventions

  • Sofosbuvir 400 mg tablet administered orally once daily

    Also known as: Sovaldi®, GS-7977, PSI-7977

  • DrugRBV

    Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy

    SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment.

    Time frame: Posttreatment Week 12

  2. Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Percentage of Participants With Sustained Virologic Response at 4 Weeks After Discontinuation of Therapy (SVR4)

    SVR4 was defined as HCV RNA \< LLOQ at 4 weeks following the last dose of study drug.

    Time frame: Posttreatment Week 4

  2. Percentage of Participants Experiencing Viral Breakthrough

    Viral breakthrough was defined as either: * HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while receiving treatment * HCV RNA ≥ LLOQ at the last available on-treatment measurement with no subsequent follow-up values

    Time frame: Up to Posttreatment Weak 12

  3. Percentage of Participants Experiencing Viral Relapse

    Viral relapse was defined as HCV RNA ≥ LLOQ during the posttreatment period after having achieved HCV RNA \< LLOQ at end of treatment.

    Time frame: Up to Posttreatment Week 12

  4. Number of Participants With Nonstructural Protein 5B (NS5B) Nucleoside Inhibitor (NI) Resistance-Associated Variants (RAVs) and RBV RAVs at Pretreatment and Posttreatment

    Deep sequencing of the HCV NS5B gene was attempted for all participants who had virologic failure at pretreatment and posttreatment time points if the level of HCV RNA in the plasma sample was ≥ 1000 IU/L.

    Time frame: Pretreatment and Posttreatment Week 12

07

Results

Posted Aug 3, 2016
Limitations and caveats
There were no limitations affecting the analysis or results.

Participant flow

Participants were enrolled at a total of 15 study sites in the United States The first participant was screened on 04 June 2014. The last study visit occurred on 22 June 2015.

Participant flow — Overall Study
MilestoneSOF+RBV 12 Weeks (TN)SOF+RBV 12 Weeks (TE)
Started4719
Completed4319
Not completed40
Withdrew: Lost to follow-up30
Withdrew: Withdrew consent10

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy

SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment.

Time frame:
Posttreatment Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy
Percentage of participantsSOF+RBV 12 Weeks (TN)SOF+RBV 12 Weeks (TE)
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy76.6 (62.0 to 87.7)84.2 (60.4 to 96.6)
PrimaryPercentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
Time frame:
Up to 12 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
Percentage of participantsSOF+RBV 12 Weeks (All)
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event4.5
SecondaryPercentage of Participants With Sustained Virologic Response at 4 Weeks After Discontinuation of Therapy (SVR4)

SVR4 was defined as HCV RNA \< LLOQ at 4 weeks following the last dose of study drug.

Time frame:
Posttreatment Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response at 4 Weeks After Discontinuation of Therapy (SVR4)
percentage of participantsSOF+RBV 12 Weeks (TN)SOF+RBV 12 Weeks (TE)
Percentage of Participants With Sustained Virologic Response at 4 Weeks After Discontinuation of Therapy (SVR4)78.7 (64.3 to 89.3)89.5 (66.9 to 98.7)
SecondaryPercentage of Participants Experiencing Viral Breakthrough

Viral breakthrough was defined as either: * HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while receiving treatment * HCV RNA ≥ LLOQ at the last available on-treatment measurement with no subsequent follow-up values

Time frame:
Up to Posttreatment Weak 12
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing Viral Breakthrough
Percentage of participantsSOF+RBV 12 Weeks (TN)SOF+RBV 12 Weeks (TE)
Percentage of Participants Experiencing Viral Breakthrough00
SecondaryPercentage of Participants Experiencing Viral Relapse

Viral relapse was defined as HCV RNA ≥ LLOQ during the posttreatment period after having achieved HCV RNA \< LLOQ at end of treatment.

Time frame:
Up to Posttreatment Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing Viral Relapse
Percentage of participantsSOF+RBV 12 Weeks (TN)SOF+RBV 12 Weeks (TE)
Percentage of Participants Experiencing Viral Relapse17.415.8
SecondaryNumber of Participants With Nonstructural Protein 5B (NS5B) Nucleoside Inhibitor (NI) Resistance-Associated Variants (RAVs) and RBV RAVs at Pretreatment and Posttreatment

Deep sequencing of the HCV NS5B gene was attempted for all participants who had virologic failure at pretreatment and posttreatment time points if the level of HCV RNA in the plasma sample was ≥ 1000 IU/L.

Time frame:
Pretreatment and Posttreatment Week 12
Reported as:
Number · participants
Number of Participants With Nonstructural Protein 5B (NS5B) Nucleoside Inhibitor (NI) Resistance-Associated Variants (RAVs) and RBV RAVs at Pretreatment and Posttreatment
participantsSOF+RBV 12 Weeks (All)
NS5B NI RAV Pretreatment2
NS5B NI RAV Posttreatment5
NS5B RBV RAV Pretreatment0
NS5B RBV RAV Posttreatment0

Adverse events

Collected over Up to12 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SOF+RBV 12 Weeks (All Participants)—8/66 (12.1%)45/66 (68.2%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventSOF+RBV 12 Weeks (All Participants)
AnaemiaBlood and lymphatic system disorders1/66
Cardiac failure congestiveCardiac disorders1/66
NauseaGastrointestinal disorders1/66
Oesophageal varices haemorrhageGastrointestinal disorders1/66
Chest painGeneral disorders1/66
BacteraemiaInfections and infestations1/66
Endocarditis staphylococcalInfections and infestations1/66
SepsisInfections and infestations1/66
RhabdomyolysisMusculoskeletal and connective tissue disorders1/66
Drug withdrawal convulsionsNervous system disorders1/66
Most frequent other events
Showing 10 of 13
Most frequent other events
EventSOF+RBV 12 Weeks (All Participants)
FatigueGeneral disorders22/66
AnaemiaBlood and lymphatic system disorders16/66
NauseaGastrointestinal disorders12/66
HeadacheNervous system disorders11/66
DizzinessNervous system disorders6/66
DyspnoeaRespiratory, thoracic and mediastinal disorders5/66
RashSkin and subcutaneous tissue disorders5/66
DiarrhoeaGastrointestinal disorders4/66
DyspepsiaGastrointestinal disorders4/66
VomitingGastrointestinal disorders4/66

Baseline characteristics

Safety analysis set: participants who received at least 1 dose of study drug

Age, Continuous
Age, Continuous(Years)SOF+RBV 12 Weeks (TN)SOF+RBV 12 Weeks (TE)Total
Mean64 ± 6.062 ± 5.463 ± 5.8
Sex: Female, Male
Sex: Female, Male(Participants)SOF+RBV 12 Weeks (TN)SOF+RBV 12 Weeks (TE)Total
Female000
Male471966
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)SOF+RBV 12 Weeks (TN)SOF+RBV 12 Weeks (TE)Total
Black or African American8210
White371754
Hawaiian or Pacific Islander101
Other101
Region of Enrollment
Region of Enrollment(participants)SOF+RBV 12 Weeks (TN)SOF+RBV 12 Weeks (TE)Total
United States471966
IL28b Status
IL28b Status(participants)SOF+RBV 12 Weeks (TN)SOF+RBV 12 Weeks (TE)Total
CC25833
CT191029
TT314
HCV RNA
HCV RNA(log10 IU/mL)SOF+RBV 12 Weeks (TN)SOF+RBV 12 Weeks (TE)Total
Mean5.9 ± 0.896.6 ± 0.486.1 ± 0.87
HCV RNA Category
HCV RNA Category(participants)SOF+RBV 12 Weeks (TN)SOF+RBV 12 Weeks (TE)Total
< 800,000 IU/mL21223
≥ 800,000 IU/mL261743
HCV Genotype
HCV Genotype(participants)SOF+RBV 12 Weeks (TN)SOF+RBV 12 Weeks (TE)Total
Genotype 2224
Genotype 2b371754
Genotype 2a/2c808

1 further baseline measures are reported on the registry.

08

Study locations

17 sites
  • Long Beach, California 90822, United States
  • Los Angeles, California 90073, United States
  • Palo Alto, California 94394, United States
  • San Diego, California 92102, United States
  • San Francisco, California 94121, United States
  • New Haven, Connecticut 06520, United States
  • Miami, Florida 33125, United States
  • Decatur, Georgia 30033, United States
  • Baltimore, Maryland 21201, United States
  • Kansas City, Missouri 64128, United States
  • Durham, North Carolina 27705, United States
  • Portland, Oregon 97239, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Pittsburgh, Pennsylvania 15240, United States
  • Dallas, Texas 75216, United States
  • Houston, Texas 77030, United States
  • Richmond, Virginia 23249, United States
09

References and documents

Publications

  • Ho SB, Monto A, Peyton A, Kaplan DE, Byrne S, Moon S, Copans A, Rossaro L, Roy A, Le H, Dvory-Sobol H, Zhu Y, Brainard DM, Guyer W, Shaikh O, Fuchs M, Morgan TR; VALOR study team. Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities. Clin Gastroenterol Hepatol. 2017 Feb;15(2):282-288. doi: 10.1016/j.cgh.2016.05.024. Epub 2016 May 27. PubMed 27237429 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2014
First posted
May 1, 2014
Start
Jun 2014
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Results first posted
Aug 3, 2016
Last update
Aug 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02128542
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
May 1, 2014
Start date
Jun 2014
Primary completion
Jun 2015
Completion
Jun 2015
Results posted
Aug 3, 2016
Last update
Aug 3, 2016

Study contacts

Lorenzo Rossaro, MD
study director · Gilead Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sofosbuvir · Ribavirin

Start the discussion